A Multicenter Study of the Efficacy and Safety of Esketamine for Analgesia During Cesarean Section
Status:
Not yet recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This study proposed applying intravenous Esketamine to cesarean section in parturient,
detecting the plasma concentration of Esketamine in maternal blood, neonatal umbilical venous
blood and umbilical arterial blood when the baby is delivered ketamine blood drug
concentration, observing vital signs, adverse visual analog pain score (VAS), and sedation
score (Ramsay) in parturient, neonatal Apgar score 1, 5 to 10 minutes after birth, the
umbilical arterial blood gas and neurobehavioral scores (NBNA) 2, 24 hours after the birth.
This study aims to address placental transfer, metabolism and analgesic and sedative effects
in neonates and parturients of Esketamine so as to explore the feasibility, efficacy and
safety of Esketamine as adjuvant medication for cesarean section.
Phase:
Phase 4
Details
Lead Sponsor:
Women's Hospital School Of Medicine Zhejiang University